美国旅行者日本脑炎疫苗接种策略的比较性经济分析
该研究采用决策树模型,从社会与旅行者视角估算美国旅行者按风险分级接种日本脑炎疫苗的需治疗人数与成本效果比。发病率升高10倍和100倍时成本效果比相应降低,医疗费用升高影响甚微。
要点
- 风险I类需治疗人数约70万,每避免一例成本约6亿美元。
- 发病率升高10倍和100倍时成本效果比成比例降低。
核心结论
- 美国旅行者接种日本脑炎疫苗预防病例的需治疗人数与成本效果比随风险类别和发病率差异很大。
- 成本效果比并非日本脑炎疫苗接种决策的唯一依据,结果可辅助不同风险与成本情景下的决策。
研究设计与样本
- 采用决策树模型,对假设的接种与未接种旅行者队列从社会与旅行者视角估算每避免一例的成本。
- 风险I类为计划在日本脑炎流行区停留≥1个月的旅行者,II类为停留<1个月且≥20%时间在乡村户外活动的短期旅行者,III类为其余所有旅行者。
- 敏感性分析包括发病率升高10倍和100倍以及医疗费用升高10倍和100倍。
主要发现
- 风险I类需治疗人数约70万,每避免一例成本约6亿美元。
- 发病率升高10倍和100倍时成本效果比成比例降低。
- 医疗费用升高10倍和100倍时成本效果比变化可忽略不计。
关键数值与推荐
- 风险I类:需治疗人数约70万,每避免一例成本约6亿美元。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Japanese encephalitis (JE) virus is the leading vaccine-preventable cause of encephalitis in Asia. For most travelers, JE risk is very low but varies based on several factors, including travel duration, location, and activities. To aid public health officials, health care providers, and travelers evaluate the worth of administering/ receiving pre-travel JE vaccinations, we estimated the numbers-needed-to-treat to prevent a case and the cost-effectiveness ratios of JE vaccination for U.S. travelers in different risk categories. METHODS: We used a decision tree model to estimate cost per case averted from a societal and traveler perspective for hypothetical cohorts of vaccinated and unvaccinated travelers. Risk Category I included travelers planning to spend ≥1 month in JE-endemic areas, Risk Category II were shorter-term (<1 month) travelers spending ≥20% of their time doing outdoor activities in rural areas, and Risk Category III were all remaining travelers. We performed sensitivity analyses including examining changes in cost-effectiveness with 10- and 100-fold increases in incidence and medical treatment costs. RESULTS: The numbers-needed-to-treat to prevent a case and cost per case averted were approximately 0.7 million and $0.6 billion for Risk Category I, 1.6 million and $1.2 billion for Risk Category II, and 9.8 million and $7.6 billion for Risk Category III. Increases of 10-fold and 100-fold in disease incidence proportionately decreased cost-effectiveness ratios. Similar levels of increases in medical treatment costs resulted in negligible changes in cost-effectiveness ratios. CONCLUSION: Numbers-needed-to-treat and cost-effectiveness ratios associated with preventing JE cases in U.S. travelers by vaccination varied greatly by risk category and disease incidence. While cost effectiveness ratios are not the sole rationale for decision-making regarding JE vaccination, the results presented here can aid in making such decisions under very different risk and cost scenarios.
引用
- Carias C, Hills SL, Kahn EB, et al. Comparative economic analysis of strategies for Japanese encephalitis vaccination of U.S. travelers. Vaccine. 2020. PMID: 32169391. doi:10.1016/j.vaccine.2020.02.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。